Company profile for Araris Biotech

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Araris Biotech AG is pioneering a novel linker technology for antibody-drug conjugates (ADCs.) Our linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering. Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich pioneering a novel antibody-drug conjugate (ADC)-linker technology. Our linker platform enables the a...
Araris Biotech AG is pioneering a novel linker technology for antibody-drug conjugates (ADCs.) Our linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering. Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich pioneering a novel antibody-drug conjugate (ADC)-linker technology. Our linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Switzerland
Address
Address
Otto-Stern-Weg 7, 8093, Zürich
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/07/04/3110196/0/en/Str%C3%BCngmann-Award-Honors-Araris-Biotech-Founding-Team-as-2025-Winner.html

GLOBENEWSWIRE
04 Jul 2025

https://www.globenewswire.com/news-release/2025/03/17/3043425/0/en/Taiho-Pharmaceutical-to-Acquire-Next-Generation-ADC-Drug-Discovery-Company-Araris-Biotech.html

GLOBENEWSWIRE
17 Mar 2025

https://www.fiercebiotech.com/biotech/roches-chugai-turns-switzerland-adc-development-deal-potentially-worth-more-780-million

FIERCE BIOTECH
10 Jan 2025

https://www.globenewswire.com/news-release/2024/11/12/2979033/0/en/Araris-Biotech-Publishes-Foundational-Science-Behind-its-Novel-Antibody-Drug-Conjugate-Platform-in-ChemBioChem.html

GLOBENEWSWIRE
12 Nov 2024

https://www.globenewswire.com/news-release/2024/09/24/2952114/0/en/Araris-Biotech-AG-Expands-its-IP-Portfolio-with-the-Acquisition-of-Innate-Pharma-s-Portfolio-of-Transglutaminase-Patents-for-the-Generation-of-Antibody-Drug-Conjugates-ADCs.html

GLOBENEWSWIRE
24 Sep 2024

https://www.globenewswire.com/news-release/2024/06/13/2898214/0/en/Araris-Biotech-AG-Appoints-Dr-Ulf-Grawunder-to-Scientific-Advisory-Board.html

GLOBENEWSWIRE
13 Jun 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty